Table 1. Clinical and demographic characteristics of the subjects studied.
| Variable | FTD (all) | GRN+ | GRN- | aGRN+ |
|---|---|---|---|---|
| n=32 | n=12 | n=20 | n=17 | |
| Age at evaluation^, y | 64.7±6.8 | 61.3±5.2 | 67.4±7.2 | 40.3±9.7 |
| Age at onset, y | 62.2±6.9 | 59.2±6.4 | 64.0±6.3 | - |
| Disease duration, y | 2.5±2.3 | 2.1±2.0 | 3.4±2.7 | - |
| Gender, female % (n) | 43.8 (14) | 66.7 (8) | 25.0 (5) | 41.2 (7) |
| Family history*, positive % (n) | 59.4 (19) | 91.7 (11) | 40.0 (8) | - |
| Clinical phenotype, bvFTD %(n) | 56.3(18) | 50.0 (6) | 60.0 (12) | - |
| FTD-CDR^ | 5.3±3.3 | 6.1±3.6 | 4.5±3.1 | - |
| CognitiveReserveIndex | ||||
| Reserve Index** | 3.65±1.32 | 3.00±0.85 | 3.40±1.27 | 4.41±1.33 |
FTD: Frontotemporal dementia; GRN+: FTD patients carrying Granulin Thr272fs mutation; GRN-: FTD patients without Granulin Thr272fs mutation; aGRN+: asymptomatic subjects carrying Granulin Thr272fs mutation; FTD-CDR: Frontotemporal dementia modified Clinical dementia rating scale.
GRN+ vs. GRN-, ^ P=0.024; *P=0.008. t-test, otherwise specified or Chi-square test were performed, as required. Results are expressed as mean ± standard deviation. Number of subjects between brackets. One way-ANOVA between the three groups (GRN+, GRN-, aGRN+), **P=0.007. See text for further details.